Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor

被引:0
作者
C R J Pameijer
A Navanjo
B Meechoovet
J R Wagner
B Aguilar
C L Wright
W-C Chang
C E Brown
M C Jensen
机构
[1] Stony Brook University Hospital,Division of General and Oncologic Surgery
[2] Beckman Research Institute,Division of Cancer Immunotherapeutics & Tumor Immunology
[3] City of Hope National Medical Center,undefined
来源
Cancer Gene Therapy | 2007年 / 14卷
关键词
T cells; chimeric immuno-receptors; phage display;
D O I
暂无
中图分类号
学科分类号
摘要
Adoptive transfer of ex vivo expanded tumor-specific T cells is a promising therapeutic modality for promoting or augmenting antitumor immunity. Several groups, including ours, are developing antigen receptor gene transfer strategies as a means of generating effector cells for adoptive therapy. Chimeric antigen receptors (CARs) have been described that use single-chain antibodies or cytokine ligands as tumor targeting domains. Here, we describe the capacity of a tumor-binding peptide identified by phage display combinatorial library screening to serve as a CAR targeting domain. A phage library-selected high-affinity 12-mer peptide (Bpep) specific for alpha(v) beta(6) integrin (αvβ6) was chosen for these studies. Primary human T cells were genetically modified to express the Bpep-CAR consisting of an αvβ6-specific peptide and human IgG4 hinge-Fc extracellular domain fused to the cytoplasmic tail of CD3-ζ. T cell expression of the Bpep-CAR was assessed by Western blot analysis, and trafficking of the Bpep-CAR to the cell surface was demonstrated by flow cytometry. Functionally, Bpep-CAR redirected cytotoxic T lymphocytes specifically kill integrin αvβ6+ ovarian tumor targets, and are activated for interferon gamma secretion. Our data suggest that large new repertoires of tumor-specific T cell antigen receptor transgenes might be available through merging combinatorial peptide libraries with CAR construct design.
引用
收藏
页码:91 / 97
页数:6
相关论文
共 64 条
  • [1] Dudley ME(2002)Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 850-854
  • [2] Wunderlich JR(2005)T-cell genetic modification for re-directed tumor recognition Cancer Chemother Biol Response Modif 22 293-324
  • [3] Robbins PF(2000)Human T lymphocyte genetic modification with naked DNA Mol Ther 1 49-55
  • [4] Yang JC(2001)Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes Int J Cancer 94 228-236
  • [5] Hwu P(2000)Specific targeting of EGP-2 Hum Gene Ther 11 9-19
  • [6] Schwartzentruber DJ(1995) tumor cells by primary lymphocytes modified with chimeric T cell receptors J Cell Sci 108 2241-2251
  • [7] Cooper LJ(2002)Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling J Histochem Cytochem 50 1371-1380
  • [8] Kalos M(2001)Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer Int J Cancer 92 40-48
  • [9] DiGiusto D(1999)The alphaVbeta6 integrin regulates its own expression with cell crowding: implications for tumour progression J Biol Chem 274 1979-1985
  • [10] Brown C(1996)Definition of an unexpected ligand recognition motif for alphavbeta6 integrin Gynecol Oncol 62 82-88